NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

10047	Companies
204831	Keywords
135087	Articles
108601	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 03/17/2025 at 21:15, 1 year ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Nanobiotix strengthens financial position by amending global licensing agreement for JNJ-1900 (NBTXR3), extending cash visibility to mid-2026. Details of the amendment and future potential milestone payments outlined

Financial Position Milestone Payments NANOBIOTIX JNJ-1900 Global Licensing Agreement
BRIEF

published on 03/13/2025 at 22:20, 1 year ago

Nanobiotix Reports Voting Rights and Share Capital Details

Euronext Paris Voting Rights Financial Transparency NANOBIOTIX Shares Outstanding
PRESS RELEASE

published on 03/13/2025 at 22:15, 1 year ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital. Detailed breakdown of outstanding shares and voting rights presented. Company overview and contact information included

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 02/12/2025 at 22:20, 1 year 1 month ago

Nanobiotix: Details on Voting Rights and Shares in January 2025

Euronext Paris Voting Rights Actions Nasdaq NANOBIOTIX
PRESS RELEASE

published on 02/12/2025 at 22:15, 1 year 1 month ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital details. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 12/17/2024 at 22:20, 1 year 3 months ago

NANOBIOTIX Prepares its Revolutionary Virtual Event

Cancer NANOBIOTIX Curadigm Nanotherapeutic Technology Intravenous Medications
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 3 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development

Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF

published on 12/09/2024 at 22:20, 1 year 3 months ago

Nanobiotix successfully completes phase 1 study in pancreatic cancer

FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 3 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025

FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study
BRIEF

published on 11/25/2024 at 09:53, 1 year 3 months ago

Threshold Crossing by Baillie Gifford at Nanobiotix

Voting Rights Capital Threshold Crossing NANOBIOTIX Baillie Gifford

Accesswire

Published on 03/18/2026 at 00:30, 42 minutes ago

Panther Minerals Announces Appointment of Rick Mah as Chief Financial Officer
Published on 03/18/2026 at 00:30, 42 minutes ago

Core Critical Metals Corp. Announces Non-Brokered LIFE Offering and Concurrent Private Placement
Published on 03/17/2026 at 23:59, 1 hour 13 minutes ago

Presentation to Swiss Mining Institute Conference
Published on 03/17/2026 at 23:10, 2 hours 2 minutes ago

Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 22:30, 2 hours 42 minutes ago

Galway Metals Appoints Red Cloud Financial Services to Provide Financial Advisory and Promotional Services

View all ACCESSWIRE

EQS Group

Published on 03/17/2026 at 23:43, 1 hour 28 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C - Daily buy back notice
Published on 03/17/2026 at 21:21, 3 hours 50 minutes ago

KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 4 hours 16 minutes ago

EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 18:07, 7 hours 4 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 7 hours 14 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 03/17/2026 at 07:00, 18 hours 12 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 7 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 7 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 7 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 7 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE